Allogene Therapeutics (ALLO)
Allogene Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
53.4M
Short interest
settlement 2026-10-15
9.3
Days to cover
+0.3 days vs prior
30.8%
Short share of volume
2026-11-02
18,512
Fails to deliver
settlement 2026-10-08
Thu 5 Nov
Next earnings
estimated date
-$112K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ALLO is 53,405,256 shares, down 6,194,861 shares over the last month. Over the last 48 readings it ranged from 18,038,394 shares (15 December 2025) to 63,385,047 shares (30 June 2026). At the reported average volume of 5.8M shares a day that is 9.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/allo" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 53,405,256 | -4.0% | 5,775,784 | 9.25 |
| 2026-09-30 | 55,606,815 | -6.7% | 6,181,659 | 9.00 |
| 2026-09-15 | 59,600,117 | +0.8% | 5,295,103 | 11.26 |
| 2026-08-31 | 59,114,784 | +0.3% | 4,866,047 | 12.15 |
| 2026-08-14 | 58,945,687 | -3.0% | 4,941,400 | 11.93 |
| 2026-07-31 | 60,753,788 | +1.7% | 6,581,334 | 9.23 |
| 2026-07-15 | 59,712,398 | -5.8% | 9,403,966 | 6.35 |
| 2026-06-30 | 63,385,047 | +32.0% | 12,327,603 | 5.14 |
| 2026-06-15 | 48,035,062 | +8.0% | 7,735,975 | 6.21 |
| 2026-05-29 | 44,480,150 | +5.2% | 6,566,258 | 6.77 |
| 2026-05-15 | 42,275,161 | +14.7% | 6,595,129 | 6.41 |
| 2026-04-30 | 36,856,587 | +1.3% | 9,925,529 | 3.71 |
| 2026-04-15 | 36,379,520 | +13.5% | 22,679,624 | 1.60 |
| 2026-03-31 | 32,060,091 | +31.3% | 6,667,499 | 4.81 |
| 2026-03-13 | 24,421,757 | +2.1% | 3,935,708 | 6.21 |
| 2026-02-27 | 23,927,216 | +19.9% | 6,048,498 | 3.96 |
| 2026-02-13 | 19,964,416 | +6.1% | 5,343,210 | 3.74 |
| 2026-01-30 | 18,819,473 | +1.0% | 7,276,484 | 2.59 |
| 2026-01-15 | 18,633,438 | +3.1% | 5,310,961 | 3.51 |
| 2025-12-31 | 18,077,704 | +0.2% | 2,840,174 | 6.36 |
| 2025-12-15 | 18,038,394 | -3.4% | 2,394,660 | 7.53 |
| 2025-11-28 | 18,663,734 | -0.2% | 2,449,799 | 7.62 |
| 2025-11-14 | 18,695,485 | -2.1% | 2,330,490 | 8.02 |
| 2025-10-31 | 19,094,028 | -2.0% | 2,485,367 | 7.68 |
| 2025-10-15 | 19,491,965 | +1.5% | 3,205,125 | 6.08 |
| 2025-09-30 | 19,201,999 | -5.3% | 3,536,813 | 5.43 |
| 2025-09-15 | 20,285,441 | +1.7% | 2,137,986 | 9.49 |
| 2025-08-29 | 19,943,094 | -18.5% | 3,797,625 | 5.25 |
| 2025-08-15 | 24,472,217 | +0.1% | 7,011,325 | 3.49 |
| 2025-07-31 | 24,454,034 | -5.7% | 3,901,958 | 6.27 |
| 2025-07-15 | 25,930,643 | -2.4% | 3,818,488 | 6.79 |
| 2025-06-30 | 26,572,188 | +2.0% | 2,558,644 | 10.39 |
| 2025-06-13 | 26,041,918 | +6.0% | 2,703,576 | 9.63 |
| 2025-05-30 | 24,567,671 | -10.2% | 2,362,601 | 10.40 |
| 2025-05-15 | 27,361,306 | -9.2% | 5,324,896 | 5.14 |
| 2025-04-30 | 30,125,461 | -8.2% | 2,247,050 | 13.41 |
| 2025-04-15 | 32,811,049 | -5.6% | 3,167,452 | 10.36 |
| 2025-03-31 | 34,756,318 | -8.6% | 3,514,828 | 9.89 |
| 2025-03-14 | 38,012,142 | -2.8% | 3,259,936 | 11.66 |
| 2025-02-28 | 39,095,990 | +16.1% | 14,864,570 | 2.63 |
| 2025-02-14 | 33,662,897 | +5.0% | 6,638,865 | 5.07 |
| 2025-01-31 | 32,048,327 | -0.9% | 2,305,377 | 13.90 |
| 2025-01-15 | 32,352,285 | +4.7% | 3,269,259 | 9.90 |
| 2024-12-31 | 30,906,822 | -4.5% | 2,890,694 | 10.69 |
| 2024-12-13 | 32,371,979 | +3.9% | 2,335,231 | 13.86 |
| 2024-11-29 | 31,167,763 | -11.1% | 2,703,155 | 11.53 |
| 2024-11-15 | 35,047,242 | -5.4% | 2,722,218 | 12.87 |
| 2024-10-31 | 37,040,821 | -5.8% | 1,953,521 | 18.96 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ALLO volume is 30.8%, down 0.9 points over the last five sessions. Over the last 30 readings it ranged from 14.2% (30 October 2026) to 69.2% (24 September 2026). The latest reading is 8.1 points below the 30-session average of 38.8%, on 5.7M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 1.7M | 5.7M | 30.8% | 497 |
| 2026-10-30 | 1.1M | 7.5M | 14.2% | 950 |
| 2026-10-29 | 791K | 4.4M | 17.8% | 1,537 |
| 2026-10-28 | 1.2M | 5.4M | 23.1% | 330 |
| 2026-10-27 | 2.7M | 10.0M | 27.3% | 600 |
| 2026-10-26 | 2.0M | 6.3M | 31.7% | 2,358 |
| 2026-10-23 | 2.2M | 5.3M | 41.8% | 100 |
| 2026-10-22 | 1.5M | 4.3M | 34.6% | 0 |
| 2026-10-21 | 1.3M | 2.8M | 46.8% | 50,538 |
| 2026-10-20 | 985K | 2.3M | 42.6% | 24,631 |
| 2026-10-19 | 1.1M | 3.4M | 31.3% | 6,485 |
| 2026-10-16 | 1.1M | 2.6M | 43.8% | 3,233 |
| 2026-10-15 | 942K | 2.5M | 37.1% | 3,678 |
| 2026-10-14 | 1.8M | 4.7M | 38.5% | 76,393 |
| 2026-10-13 | 1.3M | 3.7M | 34.1% | 9,203 |
| 2026-10-12 | 992K | 2.5M | 40.1% | 5,000 |
| 2026-10-09 | 2.5M | 7.7M | 32.1% | 2,620 |
| 2026-10-08 | 1.2M | 4.3M | 27.5% | 18,518 |
| 2026-10-07 | 820K | 2.2M | 37.2% | 500 |
| 2026-10-06 | 1.1M | 2.9M | 38.1% | 413 |
| 2026-10-05 | 798K | 2.3M | 35.0% | 0 |
| 2026-10-02 | 1.0M | 2.6M | 39.3% | 0 |
| 2026-10-01 | 1.1M | 2.9M | 38.4% | 8,661 |
| 2026-09-30 | 1.0M | 2.3M | 45.5% | 359 |
| 2026-09-29 | 850K | 1.8M | 46.1% | 38 |
| 2026-09-28 | 1.4M | 3.3M | 40.8% | 7,926 |
| 2026-09-25 | 1.3M | 2.1M | 62.5% | 2,036 |
| 2026-09-24 | 3.2M | 4.7M | 69.2% | 5,196 |
| 2026-09-23 | 2.1M | 3.3M | 63.3% | 17,526 |
| 2026-09-22 | 1.3M | 2.4M | 54.8% | 3,464 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 8 October 2026, the fails-to-deliver balance in ALLO is 18,512 shares, up 16,668 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (6 August 2026) to 6,505,279 shares (29 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-08 | 18,512 | $1.43 | $26K |
| 2026-10-01 | 1,844 | $1.60 | $3K |
| 2026-09-29 | 6,505,279 | $1.63 | $10.6M |
| 2026-09-28 | 34,042 | $1.65 | $56K |
| 2026-09-25 | 1,892 | $1.67 | $3K |
| 2026-09-17 | 14,248 | $1.69 | $24K |
| 2026-09-16 | 1,838 | $1.72 | $3K |
| 2026-09-03 | 14,927 | $1.98 | $30K |
| 2026-09-02 | 1,813 | $1.99 | $4K |
| 2026-08-31 | 1,820 | $2.02 | $4K |
| 2026-08-27 | 73,533 | $2.04 | $150K |
| 2026-08-21 | 1,878 | $2.10 | $4K |
| 2026-08-11 | 1,821 | $2.10 | $4K |
| 2026-08-07 | 1,841 | $1.97 | $4K |
| 2026-08-06 | 2 | $1.95 | $4 |
| 2026-08-03 | 1,817 | $1.88 | $3K |
| 2026-07-29 | 1,898 | $1.66 | $3K |
| 2026-07-24 | 1,872 | $1.82 | $3K |
| 2026-07-23 | 18,989 | $1.86 | $35K |
| 2026-07-16 | 1,892 | $1.90 | $4K |
| 2026-07-14 | 20,981 | $1.93 | $40K |
| 2026-07-10 | 25,000 | $2.10 | $53K |
| 2026-07-09 | 1,858 | $2.12 | $4K |
| 2026-07-06 | 1,869 | $2.08 | $4K |
| 2026-06-30 | 945,645 | $2.22 | $2.1M |
| 2026-06-26 | 1,852 | $2.06 | $4K |
| 2026-06-24 | 1,851 | $2.07 | $4K |
| 2026-06-17 | 42 | $1.90 | $80 |
| 2026-06-15 | 1,822 | $1.90 | $3K |
| 2026-06-09 | 1,871 | $1.85 | $3K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ALLO reported 2 open-market sells worth $112K in the last 90 days and no open-market buys. Latest filing: Parker Geoffrey M. (CHIEF FINANCIAL OFFICER) on 2026-10-21.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-21 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 36K | $1.34 | $49K | 1.0M |
| 2026-08-21 | Douglas Earl Martin | SVP, General Counsel | Sell | 30K | $2.12 | $63K | 488K |
| 2026-06-18 | Kazam Joshua A | Director | Exercise or conversion | 48K | $0.00 | $0 | 398K |
| 2026-04-21 | Yoshiyama Annie | SVP, Finance | Sell | 10K | $2.31 | $22K | 125K |
| 2026-03-31 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 3K | $2.50 | $7K | 195K |
| 2026-03-16 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 5K | $2.47 | $12K | 198K |
| 2026-03-16 | Chang David D | President and CEO | Sell | 48K | $2.47 | $118K | 5.2M |
| 2026-03-02 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 7K | $2.60 | $19K | 203K |
| 2026-02-02 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 8K | $1.73 | $13K | 210K |
| 2026-02-02 | Chang David D | President and CEO | Sell | 95K | $1.80 | $171K | 5.2M |
| 2026-02-02 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 24K | $1.76 | $42K | 1.3M |
| 2026-02-02 | Yoshiyama Annie | SVP, Finance | Sell | 4K | $1.72 | $7K | 130K |
| 2026-02-02 | Roberts Zachary | EVP of R&D | Sell | 36K | $1.77 | $63K | 581K |
| 2026-02-02 | Douglas Earl Martin | SVP, General Counsel | Sell | 23K | $1.76 | $40K | 565K |
| 2026-01-21 | Roberts Zachary | EVP of R&D | Sell | 26K | $1.56 | $41K | 617K |
| 2025-12-18 | Kazam Joshua A | Director | Exercise or conversion | 48K | $0.00 | $0 | 351K |
| 2025-11-17 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 786 | $1.22 | $959 | 218K |
| 2025-10-21 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 37K | $1.26 | $46K | 1.3M |
| 2025-06-10 | MESSEMER DEBORAH M. | Director | Sell | 37K | $1.42 | $52K | 107K |
| 2025-04-21 | Yoshiyama Annie | SVP, Finance | Sell | 10K | $1.41 | $14K | 131K |
| 2025-03-14 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 5K | $1.98 | $11K | 219K |
| 2025-03-14 | Chang David D | President and CEO | Sell | 47K | $1.96 | $91K | 5.3M |
| 2025-03-01 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Grant | 32K | $0.00 | $0 | 224K |
| 2025-02-18 | MESSEMER DEBORAH M. | Director | Sell | 13K | $2.43 | $32K | 144K |
| 2025-02-03 | Roberts Zachary | EVP of R&D | Sell | 19K | $1.70 | $32K | 643K |
| 2025-02-03 | Chang David D | President and CEO | Sell | 46K | $1.68 | $77K | 5.3M |
| 2025-02-03 | MOORE TIMOTHY L. | Chief Technical Officer | Sell | 15K | $1.71 | $25K | 251K |
| 2025-02-03 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 4K | $1.73 | $8K | 1.3M |
| 2025-02-03 | Douglas Earl Martin | SVP, General Counsel | Sell | 6K | $1.71 | $11K | 588K |
| 2025-01-24 | Chang David D | President and CEO | Grant | 552K | $0.00 | $0 | 5.4M |
| 2025-01-24 | Belldegrun Arie | Director | Grant | 370K | $0.00 | $0 | 2.2M |
| 2025-01-24 | Roberts Zachary | EVP of R&D | Grant | 174K | $0.00 | $0 | 662K |
| 2025-01-24 | Yoshiyama Annie | SVP, Finance | Grant | 36K | $0.00 | $0 | 138K |
| 2025-01-24 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Grant | 174K | $0.00 | $0 | 1.3M |
| 2025-01-24 | Douglas Earl Martin | SVP, General Counsel | Grant | 145K | $0.00 | $0 | 594K |
| 2025-01-21 | Roberts Zachary | EVP of R&D | Sell | 27K | $1.78 | $48K | 488K |
| 2024-12-09 | MESSEMER DEBORAH M. | Director | Sell | 9K | $2.18 | $20K | 158K |
| 2024-12-05 | Humer Franz B | Director | Sell | 9K | $2.16 | $20K | 308K |
| 2024-10-21 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Tax withholding | 36K | $2.84 | $103K | 1.1M |
| 2024-08-21 | Douglas Earl Martin | SVP, General Counsel | Tax withholding | 28K | $2.79 | $79K | 449K |
| 2024-06-18 | MESSEMER DEBORAH M. | Director | Sell | 19K | $2.28 | $43K | 167K |
| 2024-06-05 | MESSEMER DEBORAH M. | Director | Grant | 123K | $0.00 | $0 | 185K |
| 2024-06-05 | Humer Franz B | Director | Grant | 61K | $0.00 | $0 | 317K |
| 2024-06-05 | SATO VICKI L | Director | Grant | 61K | $0.00 | $0 | 163K |
| 2024-05-30 | Humer Franz B | Director | Sell | 11K | $2.34 | $26K | 255K |
| 2024-05-16 | Chang David D | President and CEO | Grant | 345K | $2.90 | $1.0M | 4.8M |
| 2024-05-16 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Grant | 345K | $2.90 | $1.0M | 1.2M |
| 2024-05-16 | Belldegrun Arie | Director | Grant | 345K | $2.90 | $1.0M | 540K |
| 2024-05-16 | Belldegrun Arie | Director | Buy | 1.7M | $2.90 | $5.0M | 1.7M |
| 2024-04-22 | MOORE TIMOTHY L. | Chief Technical Officer | Tax withholding | 17K | $3.47 | $60K | 265K |
| 2024-03-14 | Chang David D | President and CEO | Tax withholding | 53K | $4.33 | $231K | 4.5M |
| 2024-01-30 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Buy | 190 | $3.60 | $684 | 820K |
| 2024-01-25 | Chang David D | President and CEO | Grant | 318K | $0.00 | $0 | 4.5M |
| 2024-01-25 | Roberts Zachary | EVP of R&D | Grant | 140K | $0.00 | $0 | 515K |
| 2024-01-25 | Belldegrun Arie | Director | Grant | 212K | $0.00 | $0 | 1.9M |
| 2024-01-25 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Grant | 29K | $0.00 | $0 | 819K |
| 2024-01-25 | Douglas Earl Martin | SVP, General Counsel | Grant | 42K | $0.00 | $0 | 478K |
| 2024-01-25 | MOORE TIMOTHY L. | Chief Technical Officer | Grant | 97K | $0.00 | $0 | 283K |
| 2024-01-22 | Roberts Zachary | EVP of R&D | Tax withholding | 25K | $3.17 | $78K | 375K |
| 2023-12-18 | MESSEMER DEBORAH M. | Director | Sell | 19K | $2.70 | $50K | 62K |
| 2023-10-16 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Grant | 400K | $0.00 | $0 | 400K |
| 2023-10-16 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Grant | 390K | $0.00 | $0 | 790K |
| 2023-08-14 | Douglas Earl Martin | GENERAL COUNSEL | Grant | 109K | $0.00 | $0 | 109K |
| 2023-08-14 | Douglas Earl Martin | GENERAL COUNSEL | Grant | 327K | $0.00 | $0 | 436K |
| 2023-08-10 | CHEN YINLIN JACK | SVP, Finance | Grant | 11K | $0.00 | $0 | 89K |
| 2023-08-07 | Mayo Stephen | Director | Sell | 10K | $4.29 | $43K | 25K |
| 2023-06-13 | WITTE OWEN N. | Director | Grant | 75K | $0.00 | $0 | 293K |
| 2023-06-13 | Humer Franz B | Director | Grant | 75K | $0.00 | $0 | 266K |
| 2023-06-13 | SATO VICKI L | Director | Grant | 60K | $0.00 | $0 | 101K |
| 2023-06-13 | MESSEMER DEBORAH M. | Director | Grant | 75K | $0.00 | $0 | 81K |
| 2023-04-24 | MOORE TIMOTHY L. | Chief Technical Officer | Grant | 186K | $0.00 | $0 | 186K |
| 2023-04-01 | Smith Lillian | VP, Corporate Counsel | Grant | 57K | $0.00 | $0 | 140K |
| 2023-03-22 | Chang David D | President and CEO | Grant | 1.9M | $0.00 | $0 | 4.2M |
| 2023-03-22 | Belldegrun Arie | Director | Grant | 1.3M | $0.00 | $0 | 1.7M |
| 2023-03-22 | Roberts Zachary | EVP of R&D | Grant | 148K | $0.00 | $0 | 400K |
| 2023-03-22 | SCHMIDT ERIC THOMAS | Chief Financial Officer | Grant | 558K | $0.00 | $0 | 862K |
| 2023-03-22 | MOORE ALISON | Chief Technical Officer | Grant | 558K | $0.00 | $0 | 673K |
| 2023-03-14 | Bhavnagri Veer | General Counsel | Tax withholding | 24K | $5.67 | $134K | 556K |
| 2023-03-14 | MOORE ALISON | Chief Technical Officer | Tax withholding | 8K | $5.51 | $46K | 115K |
| 2023-03-14 | SCHMIDT ERIC THOMAS | Chief Financial Officer | Tax withholding | 36K | $5.47 | $196K | 304K |
| 2023-03-14 | Chang David D | President and CEO | Tax withholding | 22K | $5.56 | $124K | 2.3M |
| 2023-02-13 | Bhavnagri Veer | General Counsel | Sell | 3K | $6.85 | $21K | 578K |
| 2023-01-20 | Roberts Zachary | EVP of R&D | Grant | 252K | $0.00 | $0 | 252K |
| 2023-01-17 | Bhavnagri Veer | General Counsel | Sell | 3K | $7.04 | $21K | 581K |
| 2022-12-15 | Bhavnagri Veer | General Counsel | Sell | 6K | $7.53 | $42K | 584K |
| 2022-10-07 | Amado Rafael | EVP of R&D | Tax withholding | 8K | $11.83 | $100K | 542K |
| 2022-10-07 | Amado Rafael | EVP of R&D | Grant | 19K | $0.00 | $0 | 550K |
| 2022-10-03 | Amado Rafael | EVP of R&D | Tax withholding | 9K | $11.06 | $99K | 531K |
| 2022-08-12 | WITTE OWEN N. | Director | Sell | 5K | $17.25 | $86K | 218K |
| 2022-08-11 | WITTE OWEN N. | Director | Sell | 10K | $16.50 | $165K | 223K |
| 2022-08-02 | Amado Rafael | EVP of R&D and CMO | Sell | 2K | $11.97 | $24K | 540K |
| 2022-07-08 | Mayo Stephen | Director | Grant | 35K | $0.00 | $0 | 35K |
| 2022-07-05 | Amado Rafael | EVP of R&D and CMO | Sell | 2K | $11.44 | $23K | 542K |
| 2022-06-22 | WITTE OWEN N. | Director | Sell | 10K | $11.76 | $118K | 233K |
| 2022-06-21 | Amado Rafael | EVP of R&D and CMO | Sell | 2K | $11.18 | $22K | 544K |
| 2022-06-15 | WITTE OWEN N. | Director | Grant | 22K | $0.00 | $0 | 243K |
| 2022-06-15 | Kazam Joshua A | Director | Grant | 44K | $0.00 | $0 | 303K |
| 2022-06-15 | SATO VICKI L | Director | Grant | 22K | $0.00 | $0 | 41K |
| 2022-06-15 | Humer Franz B | Director | Grant | 44K | $0.00 | $0 | 192K |
| 2022-05-19 | Amado Rafael | EVP of R&D and CMO | Sell | 12K | $7.40 | $85K | 546K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON16 Form 144 notices on file for ALLO worth $998K at the prices reported; 2 in the last 90 days worth $112K. Latest: Parker Geoffrey M. filed on 2026-10-21 to sell 36,342 shares ($49K) from 2026-10-21.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-21 | Parker Geoffrey M.Officer | 36K | $49K | 0.011% | 2026-10-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-21 | Douglas Earl MartinOfficer | 30K | $63K | 0.009% | 2026-08-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-21 | Yoshiyama AnnieOfficer | 10K | $22K | 0.004% | 2026-04-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-01 | Beneski Benjamin MachinasOfficer | 3K | $7K | 0.001% | 2026-04-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | Beneski Benjamin MachinasOfficer | 5K | $12K | 0.002% | 2026-03-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | Chang David DOfficer | 48K | $118K | 0.020% | 2026-03-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | Beneski Benjamin MachinasOfficer | 7K | $19K | 0.003% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-02 | EARL DOUGLASOfficer | 23K | $40K | 0.010% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-02 | GEOFFREY M PARKEROfficer | 24K | $42K | 0.011% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-02 | ZACHARY J ROBERTSOfficer | 36K | $63K | 0.016% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-02 | ANNIE T YOSHIYAMAOfficer | 4K | $7K | 0.002% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-02 | DAVID CHANGOfficer | 244K | $439K | 0.109% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-02 | BENJAMIN M BENESKIOfficer | 17K | $29K | 0.007% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-21 | Roberts ZacharyOfficer | 26K | $41K | 0.012% | 2026-01-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-17 | Beneski Benjamin MachinasOfficer | 786 | $959 | 0.000% | 2025-11-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-21 | Parker Geoffrey M.Officer | 37K | $46K | 0.017% | 2025-10-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON6 holders report 5% or more of ALLO in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Pfizer Inc. at 9.0% of the class (22,032,040 shares), filed 2026-02-13 for an event on 2025-11-06.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 3 | BlackRock, Inc.parent holding company | 23.2M | 6.7% | 2026-09-30 |
| 2026-09-30 | 13D/Ano. 5 | TPG GP A, LLCother entity | 0 | 0.0% | 2026-09-28 |
| 2026-09-30 | 13D/Ano. 5 | James G. Coulterindividual | 0 | 0.0% | 2026-09-28 |
| 2026-09-30 | 13D/Ano. 5 | Jon Winkelriedindividual | 0 | 0.0% | 2026-09-28 |
| 2026-08-14 | 13G/Ano. 1 | Frazier Life Sciences Public Fund, L.P.partnership | 19.4M | 5.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLSP, L.L.C.other entity | 19.4M | 5.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLSP, L.P.partnership | 19.4M | 5.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLS XII, L.P.partnership | 1.9M | 0.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Frazier Life Sciences XII, L.P.partnership | 1.9M | 0.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLS XII, L.L.C.other entity | 1.9M | 0.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLS XI, L.L.C.other entity | 753K | 0.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Frazier Life Sciences XI, L.P.partnership | 753K | 0.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLS XI, L.P.partnership | 753K | 0.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | James N. Topperindividual | 307K | 0.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Frazier Life Sciences X, L.P.partnership | 307K | 0.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Patrick J. Heronindividual | 307K | 0.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLS X, L.P.partnership | 307K | 0.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLS X, L.L.C.other entity | 307K | 0.1% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 11 | Arie Belldegrun, M.D.individual | 13.6M | 3.9% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 11 | Bellco Legacy IV LLCother entity | 4.7M | 1.3% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 11 | Vida Ventures LLCother entity | 1.8M | 0.5% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 11 | Vida Ventures III, L.P.other entity | 1.7M | 0.5% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 11 | Bellco Legacy LLCother entity | 540K | 0.2% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 11 | Vida Ventures III-A, L.P.other entity | 4K | 0.0% | 2026-06-30 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 19.0M | 5.5% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 1 | Kenneth Griffinparent holding company, individual | 6.9M | 2.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel Advisors LLCinvestment adviser, parent holding company, other entity | 5.8M | 2.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel Advisors Holdings LPparent holding company, partnership | 5.8M | 2.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel GP LLCparent holding company, other entity | 5.8M | 2.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel Securities GP LLCparent holding company, other entity | 1.1M | 0.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel Securities Group LPparent holding company, partnership | 1.1M | 0.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel Securities LLCbroker-dealer, other entity | 614K | 0.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Weston Nicholsindividual | 0 | 0.0% | 2025-12-31 |
| 2026-05-15 | 13G/Ano. 1 | Lynx1 Capital Management LPpartnership | 0 | 0.0% | 2025-12-31 |
| 2026-05-13 | 13G/Ano. 1 | David D. Chang, M.D., Ph.D.individual | 12.3M | 4.9% | 2026-03-31 |
| 2026-05-13 | 13G/Ano. 1 | Chang 2006 Family Trustother entity | 1.2M | 0.5% | 2026-03-31 |
| 2026-05-13 | 13G/Ano. 1 | JEC 2019 Trustother entity | 856K | 0.3% | 2026-03-31 |
| 2026-05-13 | 13G/Ano. 1 | RTC 2019 Trustother entity | 856K | 0.3% | 2026-03-31 |
| 2026-02-13 | 13D/Ano. 4 | Pfizer Inc.corporation | 22.0M | 9.0% | 2025-11-06 |
| 2025-11-13 | 13G/Ano. 1 | Capital World Investorsinvestment adviser | 0 | 0.0% | 2025-09-30 |
13F holders
Tracked managers holding ALLO at their latest 13F. JSON6 of the 30 tracked managers held ALLO at their latest 13F, $69.2M in total at quarter-end prices. Citadel Advisors is the largest at $21.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 10.1M | $21.0M | 0.00% | +3.3M |
| Two Sigma Investments | 2026-06-30 | 7.8M | $16.2M | 0.01% | +2.4M |
| Millennium Management | 2026-06-30 | 4.8M | $10.1M | 0.00% | +1.5M |
| D. E. Shaw & Co. | 2026-06-30 | 4.7M | $9.8M | 0.00% | +1.9M |
| Renaissance Technologies | 2026-06-30 | 3.8M | $8.0M | 0.01% | +1.7M |
| AQR Capital Management | 2026-06-30 | 2.0M | $4.2M | 0.00% | -478K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Allogene Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Allogene Therapeutics (ALLO), SEC CIK 1737287, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-08.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-21.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-12.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-21.JSON and CSV
- Company record
- EDGAR filing index for CIK 1737287Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ALLO is sold short?
53,405,256 shares were held short at the 2026-10-15 settlement, 9.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ALLO's daily short volume?
On 2026-11-02, 1,743,936 of the 5,663,617 ALLO shares reported to FINRA were sold short, 30.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ALLO have fails to deliver?
The SEC's latest file shows 18,512 ALLO shares failed to deliver at settlement 2026-10-08. Fails are reported per settlement date and published twice a month with a lag.
Are ALLO insiders buying or selling?
Insiders at ALLO reported 2 open-market sells worth $112K in the last 90 days and no open-market buys. Latest filing: Parker Geoffrey M. (CHIEF FINANCIAL OFFICER) on 2026-10-21.
Have ALLO insiders filed to sell?
16 Form 144 notices on file for ALLO worth $998K at the prices reported; 2 in the last 90 days worth $112K. Latest: Parker Geoffrey M. filed on 2026-10-21 to sell 36,342 shares ($49K) from 2026-10-21.
Who owns 5% or more of ALLO?
6 holders report 5% or more of ALLO in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Pfizer Inc. at 9.0% of the class (22,032,040 shares), filed 2026-02-13 for an event on 2025-11-06.
Which tracked 13F managers own ALLO?
6 of the 30 tracked 13F managers held ALLO shares at their latest filing, $69.2M in all. The largest: Ken Griffin's Citadel Advisors (10.1M shares, $21.0M), Two Sigma Investments (7.8M shares, $16.2M), Izzy Englander's Millennium Management (4.8M shares, $10.1M), D. E. Shaw & Co. (4.7M shares, $9.8M), Renaissance Technologies (3.8M shares, $8.0M), Cliff Asness's AQR Capital Management (2.0M shares, $4.2M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.